Intellectual Property India Publishes Patent Application for Bifunctional Compounds Containing 2,5-Substituted Pyrimidine Derivatives For Degrading Cyclin-Dependent Kinase 2 And Cyclin-Dependent Kinase 4 Via Ubiquitin Proteasome Pathway

MUMBAI, India, July 13 -- Intellectual Property India has published a patent application (202617074035 A) filed by Nikang Therapeutics, Inc. on June 15, 2026, for Bifunctional Compounds Containing 2,5-Substituted Pyrimidine Derivatives For Degrading Cyclin-Dependent Kinase 2 And Cyclin-Dependent Kinase 4 Via Ubiquitin Proteasome Pathway.

Inventors include Yu, Zhiyong; and Lou, Yan.

The application for the patent was published on July 10, 2026, under issue no. 28/2026.

Abstract: The present disclosure provides certain bifunctional compounds that cause degradation of Cyclin-dependent kinase 2 (CDK2) and Cyclin- dependent kinase 4 (CDK4)via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by CDK2 ...